Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762503 | 0.86 | KMT2A (0.61) | KMT2AMAPTGAAMAPK1NPSR1 | |
| SCHEMBL231457 | 0.84 | KMT2A (0.72) | KMT2AMAPTGAAMAPK1HTT | |
| SCHEMBL752917 | 0.84 | KMT2A (0.72) | KMT2AMAPTGAAMAPK1HTT | |
| SCHEMBL3656114 | 0.83 | MAPK1 (0.57) | KMT2AMAPTMAPK1HTTSMN1; SMN2 | |
| Aklomide SCHEMBL328368 | 0.82 | KMT2A (1.00) | KMT2AMAPTGAAMAPK1HTT | |
| SCHEMBL11054244 | 0.82 | KMT2A (0.70) | KMT2AMAPTGAAMAPK1HTT | |
| SCHEMBL8447117 | 0.82 | KMT2A (0.70) | KMT2AMAPTGAAMAPK1HTT | |
| SCHEMBL8447120 | 0.82 | KMT2A (0.70) | KMT2AMAPTGAAMAPK1HTT | |
| Potassium Ion SCHEMBL11056843 | 0.82 | KMT2A (0.70) | KMT2AMAPTGAAMAPK1HTT | |
| Hydrochloric Acid SCHEMBL6222540 | 0.82 | KMT2A (0.70) | KMT2AMAPTGAAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | OBI PHARMA, INC. (TW) | 2023-10-03 | — | — | US | disclosed |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | OBI PHARMA, INC. (TW) | 2023-10-03 | — | — | US | disclosed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220106339-A1 | Methods of Making High Enantioselective Secondary Alcohols | OBI PHARMA, INC. (TW) | 2022-04-07 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| EP-3265088-A1 | SREBP BLOCKERS FOR USE IN TREATING LIVER FIBROSIS, ELEVATED CHOLESTEROL AND INSULIN RESISTANCE | Medivation Technologies LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1590314-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069782-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
| US-5155268-A | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides | THE UPJOHN COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0164865-B1 | N-(AMINOALKYLPHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | THE UPJOHN COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0164865-A1 | N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4490540-A | FUNGICIDES, ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-12-25 | — | — | US | disclosed |
| EP-0052905-B1 | NOVEL (2-ARYL-4-PHENYLTHIOALKYL-1,3-DIOXOLAN-2-YL-METHYL)AZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-03 | — | — | EP | disclosed |
| EP-0052905-A1 | Novel (2-aryl-4-phenylthioalkyl-1,3-dioxolan-2-yl-methyl)azole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106339-A1 | Methods of Making High Enantioselective Secondary Alcohols | ADH5, OSTC, ADH1A | KMT2A 2667/4885MAPT 3446/4885GAA 1623/4885 |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | KMT2A 825/4885MAPT 433/4885GAA 3204/4885 |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | CXCR2, CXCR1, MMP8 | KMT2A 3815/4885MAPT 4526/4885GAA 4554/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | KMT2A 3146/4885MAPT 4172/4885GAA 614/4885 |
| US-11773118-B2 | Methods of making high enantioselective secondary alcohols | ADH5, OSTC, ADH1A | KMT2A 2667/4885MAPT 3446/4885GAA 1623/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | KMT2A 3146/4885MAPT 4172/4885GAA 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.